Company Listing
Alnylam

Alnylam is developing novel RNA interference- (RNAi-) based therapeutics that use double-stranded RNA to prevent the expression of specific genes. The company has several programmes in clinical development. It was formed from the merger of Ribopharma, the first RNAi-therapeutics company, which was founded with funding from Abingworth, and Alnylam. Alnylam went public in May 2004.

BACK
Location
Cambridge, Massachusetts
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Alnylam is developing novel RNA interference- (RNAi-) based therapeutics that use double-stranded RNA to prevent the expression of specific genes. The company has several programmes in clinical development. It was formed from the merger of Ribopharma, the first RNAi-therapeutics company, which was founded with funding from Abingworth, and Alnylam. Alnylam went public in May 2004.

Location
Cambridge, Massachusetts
Website Address
BACK
 
Copyright Abingworth 2017